/Bill Langbein

About Bill Langbein

Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work. One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma and medical devices, small companies typically fly under the radar of investors. The emergence of precision medicine, however, reduces the volatility of small cap companies and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies that would benefit patients and investors the most.

FDA Creating New Investment Opportunities in BioTech Stocks

Because FDA marketing clearance to sell a drug or device [...]

ARMO Biosciences (ARMO) – SanaCurrents Case Study

ARMO Biosciences (ARMO) listed in January 2018 at $17 per [...]

Eiger Biopharmaceuticals (NASDAQ:EIGR) – SanaCurrents Case Study

Eiger Biopharmaceuticals (NASDAQ:EIGR), a company developing treatment for rare diseases, [...]

MyoKardia (NASDAQ:MYOK) – SanaCurrents Case Study

MyoKardia (NASDAQ:MYOK), a leading precision cardiovascular medicine company, reported good [...]

Dynavax’s (NASDAQ:DVAX) – SanaCurrents Case Study

Dynavax's (NASDAQ:DVAX) BLA application for its Hepatitis B vaccine first [...]

Zogenix (NASDAQ:ZGNX) – SanaCurrents Case Study

California-based company Zogenix (NASDAQ:ZGNX) observed the drug fenfluramine, which had [...]